GLP1_NEW

Liraglutide and CPAP 3.0 mg injection once daily

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

CPAPLIRA_SC_3p0MG_QD

Trials: 1
Participants in these arms: 10

All doses pooled: Liraglutide and CPAP injection

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Overweight or obesity without diabetes (adults)	Discontinuation due to adverse events	longest follow-up	Placebo	HR 1.67 (0.09 to 25.83)	0.51
Overweight or obesity without diabetes (adults)	Discontinuation due to gastrointestinal adverse events	longest follow-up	Placebo	HR 4.03 (0.17 to 77.59)	0.36

Trials

NCT04186494
The Benefit of a Liraglutide-based Weight Management Alone or in Addition to Standard CPAP Therapy on Metabolic Function in Patients With Obstructive Sleep Apnoea (OSA) - an Explorative, Proof-of-concept Study
2019 · 30 randomized · 24 weeks

Liraglutide and CPAP 3.0 mg injection once daily

Related

Effects across outcomes

Trials